Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What browser are you using? I still have Trade Archetech on Chromium and Mozilla. Definitely dread when it is no longer available. Can't make heads or tails out of ThinkorSwim.
Thanks, but I was burned quite a lot with CYTR calls. Also, I don't have a lot of faith that ADXS will be above $5 by October. While I believe that eventually both will make at least some recovery, who knows what the time table will be. What I am hoping is that one or the other will receive a buyout at a decent(?) price and then I will put part of the proceeds into the other and wait for it to appreciate.
Re: Hovacre, EXACTLY
Anyone with ADXS? I am tempted to sell one or the other and double down on the one remaining. Decisions... decisions....decisions???
Depends on how you count off the days. Proxy materials must be posted on web site 40 days before meeting. I suppose that July 1 would meet requirement. That date falls on Sunday, so we could probably see posting anytime up to midnight on Sunday . . . or perhaps Monday would still qualify. All assumes that meeting will actually be held on August 9. With this company, who the hell knows.
Sounds like you might be a candidate for Judge Judy. She specializes in "Dog on Dog."
As long as that pop is from a champagne bottle!
This is the response that I received regarding shareholder questions during the webcast on Monday:
Thank you for your email. Our plan is to open the line for select questions from shareholders, time permitting.
Cara Birardi ¦ Corporate Secretary ¦CytRx Corporation
True, but you have to filter through too much drivel to get anything worthwhile.
Everybody hibernating?
three pointing back at HIM (you) Borrowed from Solid Rock by Dire Straits no doubt . . . arguably the best rock group of the 70's
If true and followed through with (grammar), this is also very important.
CytRx will continue to provide updates on the progress of both aldoxorubicin (by its licensee NantCell) and the discovery laboratory activities around its innovative LADR candidates.
The Agreement also provides that NantCell will take over the development, manufacturing and commercialization responsibility for aldoxorubicin, thereby enabling us to eliminate our future research and development activities related to aldoxorubicin, although we have agreed to reimburse NantCell for payment up to a maximum of $4.2 million plus one half of any amounts in excess thereof.
This agreement was subsequent to the original (Oct 3). After receiving so little upfront cash (even this cost the company shares), why would they agree to something like this?
No matter how diminutive, you certainly have a way with "wurds."
Knox (if I may refer to you so diminutively), my take on todays's PR:
It was certainly not the news that I would have liked to hear about (e. g., NDA filing or trial results). That being said, it is the first time that I remember SK being up front on the reason for not meeting a previous objective's timeline. For once he has not left us dangling in the wind. While this PR will probably not move the share price very much, hopefully it will help in establishing a base above $2. If it can stay above $2 through the November 15 deadline for maintaining Nasdaq listing rather than drifting down to $1, I believe that will be at least a "moral victory" for the people long on the company. When and of course IF the SP gets above $6.90, then for me it becomes much more than a moral victory.
Regarding the 2-1 vote, remember that the outcome is not determined like a political election. They needed a majority of outstanding shares to vote yes for the RS to to be approved. If I remember correctly, the 80+ million affirmative votes was not that great a margin
Questions for someone who is attending to ask tomorrow:
Most obvious: Does company stand by July Presentation goal of submitting NDA in 4th quarter
Has NantCell submitted development plan to company and if so, will company share with shareholders
Explanation of why the SCLC result considered "confidential"
Or, ala Bill O'Reilly, get mad at God
I believe that his colon became a decimal point. Oct 27 at 10:00 a.m.
Those excerpts were from the proxy statements, DEF the original and DEFA the revised
From DEFA-14A
Are there any other changes to the Definitive Proxy Statement?
Except as described in this Supplement all the disclosures in the Definitive Proxy Statement remain in effect.
From DEF-14A
Will my shares be voted if I do not return my proxy card?
If your shares are held by a broker in "street name", the brokerage firm has authority under the rules of the New York Stock Exchange to vote customers' unvoted shares on "routine" matters only. Under these rules, the Proposal to amend our Restated Certificate is considered routine so, if you do not give your broker instructions, your shares will be voted by your broker with respect to the Proposal.
I believe that there is a difference between actively voting "abstain" and not voting altogether. If you abstain your ballot is effectively cast and off limit to brokers voting your shares. If you don't vote at all, then brokers can vote your shares. The question then is whether or not the RS is considered "routine."
If routine then shares normally will be voted in favor of the issue.
While I did remember the share price for the Ocata buyout, I couldn't recall the total price. Looked it up to find out that it was $379 million. This was for a company (while all of us shareholders thought it was worth lots more) that had not even begun to start recruiting for Phase 2. I can't conceive that Cytrx is intrinsically worth less, so IMO the floor for a buyout (should one occur) would have to be approximately $400 million. At present shares outstanding this would equate to $2.40/share. Back in my fantasy days I would never have even considered such a "lowball" offer. Now I would be hard pressed not to accept it.
Out of the frying pan, into the fire!
Damned if they do, damned if they don't!
One foot in the grave and the other foot on a banana peel!
Agree completely. While redacting the terms of the collaboration is not unheard of, the failure to announce the results of the SCLC trial is unconscionable. Complete lack of concern for shareholders. Don't understand why this was not treated as a material event and necessary to file a 8-K.
Options and warrants will be affected by RS in same manner as issued shares
Finally, a voice of reason. And yes, it is hard to keep track of some posters without a scorecard.
Yes, but all the "naked" short shares will have to be resolved.
I have never fully subscribed to the idea that there are, in fact, "naked shorts". However, if there are such "critters," how might the below affect them?
After the effectiveness of the Reverse Stock Split, our Common Stock will have a new CUSIP number, which is used to identify our equity securities, and stock certificates with the older CUSIP number will need to be exchanged for certificates with the new CUSIP number by following the procedures described below.
Unfortunately, if there is a buyout any time soon, $2 may be an overly optimistic expectation.
Depending on how long they have been held and what type of account they are in, it might be better to sell the higher priced shares first (assuming that a person can designate the lot). If all would be under one year and in taxable accounts then selling the higher priced shares will result in the least capital gains tax.
Any time that an entity acquires 5% ownership it has to be reported on form 13D within 10 days.
Seems there might be a few closet bears roaming around the message boards.
Well, grammatically the "article" leaves something to be desired, but who knows regarding its conclusion.
Disagree, but everyone draws their own conclusions.
The statement is somewhat ambiguous. Is the $.6 million payment only for the $13 million share purchase or does it include the $300 + million in potential milestone payments?
Such a way with words.
IMO